Author:
Gökşin Şule,Değirmencioğlu Serkan
Reference12 articles.
1. Rajan A, Kim C, Heery CR, Guha U, Gulley JL: Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers;1;Hum Vaccin Immunother,2016
2. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy;2;Nat Rev Cancer,2012
3. : Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153;Waterhouse;Cancer Chemother Pharmacol,2018
4. Johnson DB, Peng C, Sosman JA: Nivolumab in melanoma: Latest evidence and clinical potential;4;Ther Adv Med Oncol,2015
5. : Cancer immunotherapy in patients with brain metastases;Caponnetto;Cancer Immuçnol Immunother,2018